Jérome Honnorat1,2,3, Sylvain Rheims4,5,6, Déborah Guery7,3, Louis Cousyn8, Vincent Navarro8, Géraldine Picard1, Véronique Rogemond1, Alexandre Bani-Sadr9, Natalia Shor10, Bastien Joubert1,2,3, Sergio Muñiz-Castrillo1,2,3. 1. French Reference Center of Paraneoplastic Neurological Syndromes, Hospices Civils de Lyon, Hospital for Neurology and Neurosurgery Pierre Wertheimer, Lyon, France. 2. MELIS UMR Inserm 1314/ CNRS 5284, Lyon, France. 3. University Claude Bernard Lyon 1, Lyon, France. 4. Department of Functional Neurology and Epileptology, Hospices Civils de Lyon and Lyon 1 University, Lyon, France. sylvain.rheims@chu-lyon.fr. 5. Lyon's Neurosciences Research Center, INSERM U1028CNRSUMR 5292, University Claude Bernard Lyon 1, Lyon, France. sylvain.rheims@chu-lyon.fr. 6. University Claude Bernard Lyon 1, Lyon, France. sylvain.rheims@chu-lyon.fr. 7. Department of Functional Neurology and Epileptology, Hospices Civils de Lyon and Lyon 1 University, Lyon, France. 8. Epileptology Unit, Assistance Publique-Hôpitaux de Paris Groupe Hospitalier Pitié-Salpêtrière and Brain and Spine Institute (ICM; INSERM UMRS1127, CNRS UMR7225, UPMC University Paris 06), Paris, France. 9. Department of Neuroradiology, Université de Lyon, Hospices Civils de Lyon, Lyon, France. 10. Department of Neuroradiology, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Paris, France.
Abstract
OBJECTIVE: To characterize the evolution of epilepsy in patients with leucine-rich glioma inactivated 1 antibody-associated (LGI1ab) limbic encephalitis, including factors associated with drug-resistant epilepsy (DRE). METHODS: Retrospective analysis of patients with LGI1 encephalitis managed at two tertiary epilepsy centers between 2005 and 2019 and whose samples were confirmed by the French Reference Center of Paraneoplastic Neurological Syndromes. Raw clinical, biological, EEG, and MRI data were reviewed. Two endpoints were defined: (i) Epilepsy remission: patients seizure free and in whom anti-seizure medications (ASM) have been stopped for at least 1 year at the last follow-up visit (ii) DRE: patients with persistent seizures at the last follow-up despite at least two ASM used at efficacious daily dose. RESULTS: 39 patients with LGI1 encephalitis were included with a median follow-up duration of 42 months (range 13-169). All of them reported seizures at the acute phase, with faciobrachial dystonic seizures (FBDS) in 23 (59%) and other focal seizures in 38 (97%), including 4 patients (10%) with de novo status epilepticus. At the last follow-up visit, 11 patients (28%) achieved epilepsy remission. Among the 28 patients with persistent epilepsy, eight (29%) fulfilled criteria of DRE. The only factor significantly associated with epilepsy remission was the time from clinical onset of the encephalitis to initiation of the first immunomodulatory treatment, with longer delay in patients with persistent epilepsy (7.5 ± 8.9 vs 2.4 ± 1.7 months, p = 0.006). Evolution to DRE was only driven by MRI evolution. Eight of the 15 patients (53%) who developed hippocampal atrophy (p = 0.007) also suffered from drug-resistant seizures at the last follow-up. SIGNIFICANCE: In patients with LGI1 encephalitis, rapid initiation of immunomodulatory treatment favors long-term epilepsy remission. Evolution to DRE might primarily reflect the anatomical lesion of limbic structures. Determining what modalities of immune treatment may alter these outcomes requires prospective studies with long-term follow-up.
OBJECTIVE: To characterize the evolution of epilepsy in patients with leucine-rich glioma inactivated 1 antibody-associated (LGI1ab) limbic encephalitis, including factors associated with drug-resistant epilepsy (DRE). METHODS: Retrospective analysis of patients with LGI1 encephalitis managed at two tertiary epilepsy centers between 2005 and 2019 and whose samples were confirmed by the French Reference Center of Paraneoplastic Neurological Syndromes. Raw clinical, biological, EEG, and MRI data were reviewed. Two endpoints were defined: (i) Epilepsy remission: patients seizure free and in whom anti-seizure medications (ASM) have been stopped for at least 1 year at the last follow-up visit (ii) DRE: patients with persistent seizures at the last follow-up despite at least two ASM used at efficacious daily dose. RESULTS: 39 patients with LGI1 encephalitis were included with a median follow-up duration of 42 months (range 13-169). All of them reported seizures at the acute phase, with faciobrachial dystonic seizures (FBDS) in 23 (59%) and other focal seizures in 38 (97%), including 4 patients (10%) with de novo status epilepticus. At the last follow-up visit, 11 patients (28%) achieved epilepsy remission. Among the 28 patients with persistent epilepsy, eight (29%) fulfilled criteria of DRE. The only factor significantly associated with epilepsy remission was the time from clinical onset of the encephalitis to initiation of the first immunomodulatory treatment, with longer delay in patients with persistent epilepsy (7.5 ± 8.9 vs 2.4 ± 1.7 months, p = 0.006). Evolution to DRE was only driven by MRI evolution. Eight of the 15 patients (53%) who developed hippocampal atrophy (p = 0.007) also suffered from drug-resistant seizures at the last follow-up. SIGNIFICANCE: In patients with LGI1 encephalitis, rapid initiation of immunomodulatory treatment favors long-term epilepsy remission. Evolution to DRE might primarily reflect the anatomical lesion of limbic structures. Determining what modalities of immune treatment may alter these outcomes requires prospective studies with long-term follow-up.
Authors: Mar Carreño; Christian G Bien; Ali A Asadi-Pooya; Michael Sperling; Petr Marusic; Martin Elisak; Jose Pimentel; Tim Wehner; Rajiv Mohanraj; Juan Uranga; Asier Gómez-Ibáñez; Vicente Villanueva; Francisco Gil; Antonio Donaire; Nuria Bargalló; Jordi Rumià; Pedro Roldán; Xavier Setoain; Luis Pintor; Teresa Boget; Eva Bailles; Mercè Falip; Javier Aparicio; Josep Dalmau; Francesc Graus Journal: Epilepsy Res Date: 2016-12-15 Impact factor: 3.045
Authors: Agnes van Sonderen; Roland D Thijs; Elias C Coenders; Lize C Jiskoot; Esther Sanchez; Marienke A A M de Bruijn; Marleen H van Coevorden-Hameete; Paul W Wirtz; Marco W J Schreurs; Peter A E Sillevis Smitt; Maarten J Titulaer Journal: Neurology Date: 2016-09-02 Impact factor: 9.910
Authors: Eugen Trinka; Hannah Cock; Dale Hesdorffer; Andrea O Rossetti; Ingrid E Scheffer; Shlomo Shinnar; Simon Shorvon; Daniel H Lowenstein Journal: Epilepsia Date: 2015-09-04 Impact factor: 5.864
Authors: Claude Steriade; Jeffrey Britton; Russell C Dale; Avi Gadoth; Sarosh R Irani; Jenny Linnoila; Andrew McKeon; Xiao-Qiu Shao; Viviana Venegas; Christian G Bien Journal: Epilepsia Date: 2020-06-16 Impact factor: 5.864
Authors: Sarosh R Irani; Andrew W Michell; Bethan Lang; Philippa Pettingill; Patrick Waters; Michael R Johnson; Jonathan M Schott; Richard J E Armstrong; Alessandro S Zagami; Andrew Bleasel; Ernest R Somerville; Shelagh M J Smith; Angela Vincent Journal: Ann Neurol Date: 2011-03-17 Impact factor: 10.422